Dupont P, Carlier B, Marchetti M, Ducobu J, Van der Donckt C
Acta Endocrinol (Copenh). 1984 Jan;105(1):66-71. doi: 10.1530/acta.0.1050066.
The effect of cimetidine on abnormally elevated serum levels of parathyroid hormone was studied in 21 patients with secondary hyperparathyroidism due to chronic renal failure, receiving regular dialysis treatment. The concentrations of carboxyl (-COOH) and aminoterminal (-NH2) fragments of circulating immunoreactive parathyroid hormone (iPTH) were determined before and after 2 months af treatment with cimetidine 400 mg/day. All patients had, on admission, raised levels of either hormonal fragment. The mean pre-treatment value was 17.2 mU/ml for -COOH terminus (upper normal limit 6.5 mU/ml) and 5.7 mU/ml for -NH2 terminus (upper normal limit 1.9 mU/ml). At the end of cimetidine treatment the mean values were 19.9 and 5.7 mU/ml respectively for the two forms of circulating iPTH. No changes in total serum calcium, phosphate or alkaline phosphatase activity were recorded during the study. These results do not indicate any lowering effect of cimetidine on serum iPTH in chronic uraemic patients with secondary hyperparathyroidism.
对21例因慢性肾衰竭接受定期透析治疗而患有继发性甲状旁腺功能亢进的患者,研究了西咪替丁对异常升高的血清甲状旁腺激素水平的影响。在接受400毫克/日西咪替丁治疗2个月之前和之后,测定了循环免疫反应性甲状旁腺激素(iPTH)羧基(-COOH)和氨基末端(-NH2)片段的浓度。所有患者入院时,两种激素片段的水平均升高。治疗前,-COOH末端的平均值为17.2 mU/ml(正常上限为6.5 mU/ml),-NH2末端的平均值为5.7 mU/ml(正常上限为1.9 mU/ml)。西咪替丁治疗结束时,两种循环iPTH形式的平均值分别为19.9和5.7 mU/ml。研究期间未记录血清总钙、磷酸盐或碱性磷酸酶活性的变化。这些结果并未表明西咪替丁对患有继发性甲状旁腺功能亢进的慢性尿毒症患者的血清iPTH有任何降低作用。